We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ALNEV market cap is 10.5k. The company's latest EPS is EUR -28.1476 and P/E is -1031704.30.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 171k | 30k | 34k | 12k | 533k |
| Operating Income | -8.18M | -3.49M | -7.83M | -6.44M | -6.91M |
| Net Income | -7.55M | -6.14M | -11.84M | -3.55M | -8.74M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 7.63M | 13.53M | 48.55M | 55.29M | 52.56M |
| Total Liabilities | 5.87M | 3.51M | 4.65M | 5.13M | 5.03M |
| Total Equity | 1.76M | 10.02M | 43.9M | 50.17M | 47.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -8.1M | -5.65M | -9.91M | -4.45M | -1.91M |
| Investing | 42k | -221k | -18.81M | -31.56M | -11.08M |
| Financing | 7.94M | 14.65M | 51.75M | 9.99M | 6.79M |
| Market Cap | 10.5k |
| Price to Earnings Ratio | -1031704.30 |
| Price to Sales Ratio | 16.92M |
| Price to Cash Ratio | 10.17M |
| Price to Book Ratio | 189.78k |
| Dividend Yield | - |
| Shares Outstanding | 310.61k |
| Average Volume (1 week) | 738.99k |
| Average Volume (1 Month) | 608.59k |
| 52 Week Change | -95.47% |
| 52 Week High | 3.20 |
| 52 Week Low | 0.0001 |
| Spread (Intraday) | 0.01 (14.93%) |
| Company Name | Neovacs |
| Address |
3-5 impasse reille paris, paris 75014 |
| Website | https://www.neovacs.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
